Roche Pharmaceutical Development and Sales Overview
Pharma Division CER sales growth1 in %
Global top 20 products
Roche
Q1/21
Q2/21
Q3/21
Q4/21
Q1/22
Q2/22
Q3/22
Ocrevus
16
31
7
25
18
17
16
Perjeta
2
7
2
3
1
9
5
Hemlibra
33
58
37
38
30
31
23
Tecentriq
26
31
23
17
8
13
9
Actemra/RoActemra
22
12
57
21
3
-23
-42
Herceptin
-35
-35
-26
-6
-19
-11
-23
Avastin
-40
-40
-37
-30
-32
-27
-28
Xolair
-6
3
8
14
9
13
8
Mab Thera
-46
-34
-42
-26
-21
-20
-19
Kadcyla
17
21
11
16
9
18
6
Alecensa
14
25
TNKase/Activase
-17
Lucentis
-7
23 2
18
15
23
16
11
świ
3
22
-20
1
-5
-10
2
-26
-9
-39
*
Evrysdi
-
347
189
65
93
Ronapreve
-
Esbriet
-8
1
-5
Gazyva
-2
18
Phesgo
I
Pulmozyme
-23
CellCept
24
-5
-13
-3
150* 1 M
I
272
-91
-92
-7
-6
-21
-48
10
7
9
9
*
410
168
76
-7
3
52
-3
2
-3
-2
-12
-3
-20
CER = Constant Exchange Rates; * over 500%; 1Q1-Q4/21 vs Q1-Q4/20; Q1-Q3/22 vs Q1-Q3/21
148View entire presentation